Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Supplementation with GPR120 (Ffar4) ligand omega-3 does not improve survival in murine sepsis models

Castelo Branco Ramos Nakandakari S., Elliott EI., Fudoli Lins Vieira R., da Silva Rios T., Fosam A., Betim Pavan IC.

Clinical Trial on Chronic Inflammation, published in Am J Physiol Endocrinol Metab (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Am J Physiol Endocrinol Metab (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40938960
PMCID
PMC13035247
DOI
10.1152/ajpendo.00147.2025
Citations
2

Abstract (original English)

Sepsis is a condition marked by physiologic dysregulation secondary to infection and is influenced by the nutritional state. Despite several preclinical studies and clinical trials examining nutrition and supplements in sepsis, there are no clear guidelines. Omega-3 fatty acids are polyunsaturated fatty acids with anti-inflammatory properties, represented mainly by alpha-linolenic (ALA, C18:3), eicosapentaenoic (EPA, C20:5), and docosahexaenoic (DHA, C22:6). Since sepsis is characterized with high levels of inflammation and subsequent organ dysfunction, we hypothesized that omega-3 ingestion would improve sepsis survival by attenuating inflammation via activation of GPR120 in immune cells. Here, we aimed to experimentally explore the role of omega-3 and the receptor that mediates their anti-inflammatory functions, GPR120, during sepsis. To evaluate GPR120 functionality, acute inflammation was induced via lipopolysaccharide (LPS) treatment in Raw 264.7 cells, 3T3-L1 cells, bone marrow-derived macrophages, and primary adipocytes. To evaluate the impact of omega-3 in sepsis, C57BL/6J mice were supplemented with omega-3 before LPS administration or cecal ligation and puncture (CLP) surgery. GPR120 mRNA expression decreased during inflammation. Unexpectedly, omega-3 supplementation preceding CLP worsened sepsis survival in mice. In addition, omega-3 did not affect inflammatory marke

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
3T3-L1 CellsMacrophagesAnimalsMice, Inbred C57BLMiceSepsisDisease Models, AnimalInflammationLipopolysaccharidesFatty Acids, Omega-3

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research